Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Early Diagnosis Of Relapse In Acute Myeloblastic Leukemia — Serologic Detection Of Leukemia-Associated Antigens In Human Marrow, Michael A. Baker , M.D., Judith A. Falk , B.Sc., Walter H. Carter , Ph.D., Robert N. Taub , M.D., Ph.D.
Early Diagnosis Of Relapse In Acute Myeloblastic Leukemia — Serologic Detection Of Leukemia-Associated Antigens In Human Marrow, Michael A. Baker , M.D., Judith A. Falk , B.Sc., Walter H. Carter , Ph.D., Robert N. Taub , M.D., Ph.D.
Internal Medicine Publications
Abstract
We tested serial bone-marrow samples from 47 adults with acute myeloblastic leukemia in remission for reactivity with heteroantiserums to leukemia-associated antigens, to determine whether imminent relapse could be detected in patients with acute leukemia. Of 26 patients who relapsed by standard morphologic criteria, 21 had increased immunoreactivity of bone marrow for one to six months (mean, 3.7 months) before relapse. High concordance was observed between a positive test and relapse during the period of study (chi-square = 27.53, P
Human Infection From An Unidentified Erythrocyte-Associated Bacterium, Gordon L. Archer , M.D., Philip H. Coleman , D.V.M., Ph.D., Roger M. Cole , M.D., Ph.D., Richard J. Duma , M.D., Ph.D., Charles L. Johnston , Jr., M.D.
Human Infection From An Unidentified Erythrocyte-Associated Bacterium, Gordon L. Archer , M.D., Philip H. Coleman , D.V.M., Ph.D., Roger M. Cole , M.D., Ph.D., Richard J. Duma , M.D., Ph.D., Charles L. Johnston , Jr., M.D.
Internal Medicine Publications
Abstract
A 49-year-old splenectomized man had an infection from an unidentified, gram-positive, rodshaped bacterium that adhered to the majority of his peripheral-blood erythrocytes. On transmission electron microscopy, the bacterium was seen to be extraerythrocytic and was 0.2 μm wide by 1.0 to 1.7 μm long. It possessed a thick, granular cell wall, a trilamellar membrane external to the cell wall and prominent mesosomes. Attempts to cultivate the organism in vitro or to duplicate the patient's disease in splenectomized animals were unsuccessful. The patient's response suggested that the bacterium was susceptible to cell-wall-active antibiotics and to chloramphenicol but not to tetracycline. …
A Comparison Of Amphotericin B Alone And Combined With Flucytosine In The Treatment Of Cryptoccal Meningitis, John E. Bennett , M.D., William E. Dismukes , M.D., Richard J. Duma , M.D., Gerald Medoff , M.D., Merle A. Sande , M.D., Harry Gallis , M.D., John Leonard , M.D., Branch T. Fields , M.D., Major Bradshaw , M.D., Hubert Haywood , M.D., Zell A. Mcgee , M.D., Thomas R. Cate , M.D., C. Glenn Cobbs , M.D., John F. Warner , M.D., David W. Alling , M.D., Ph.D.
A Comparison Of Amphotericin B Alone And Combined With Flucytosine In The Treatment Of Cryptoccal Meningitis, John E. Bennett , M.D., William E. Dismukes , M.D., Richard J. Duma , M.D., Gerald Medoff , M.D., Merle A. Sande , M.D., Harry Gallis , M.D., John Leonard , M.D., Branch T. Fields , M.D., Major Bradshaw , M.D., Hubert Haywood , M.D., Zell A. Mcgee , M.D., Thomas R. Cate , M.D., C. Glenn Cobbs , M.D., John F. Warner , M.D., David W. Alling , M.D., Ph.D.
Internal Medicine Publications
Abstract
We compared amphotericin B therapy for cryptococcal meningitis with a newer regimen containing both amphotericin B and flucytosine. In 50 patients with 51 courses of therapy adherent to the protocol, 27 courses were with amphotericin B and 24 with the combination. Even though the combination regimen was given for only six weeks and amphotericin B for 10 weeks, the combination cured or improved more patients (16 vs. 11), produced fewer failures or relapses (three vs. 11), more rapid sterilization of the cerebrospinal fluid (P<0.001) and less nephrotoxicity (P<0.05) than did amphotericin B alone. The number of deaths was the same (five) with each regimen. Adverse reactions to flucytosine occurred in 11 of 34 patients but were not life threatening. We conclude that combined flucytosine-amphoericin B therapy is the regimen of choice in cryptococcal meningitis. (N Engl J Med 301:126–131, 1979)